For global buyers sourcing from Asia, FDA certification remains the gold standard of regulatory trust. Tianzhong Kangyuan Pharmaceutical Group Co., Ltd stands as an FDA certified gummy vitamins manufacturer China, having successfully completed two consecutive US FDA facility inspections with zero Form 483 observations. This certification covers not only finished product manufacturing but also raw material warehousing, stability testing, and distribution recordkeeping.
Manufacturing Strength Under FDA Scrutiny
The company operates a dedicated FDA-compliance wing within its 156,000㎡ campus, featuring segregated zones for allergen control (milk, soy, gluten-free validation) and a validated cleaning-in-place system that achieves <10ppm residue between campaigns. Every batch of gummy vitamins destined for the US market undergoes dual 21 CFR Part 11 compliant electronic recordkeeping, with full data integrity audits performed quarterly. For multivitamin gummies containing iron (a common FDA citation risk due to overage concerns), Tianzhong Kangyuan applies a statistical process control chart that monitors iron content at 15-minute intervals, maintaining levels within 90–110% of label claim across 72 consecutive hours of production. The factory's annual FDA-directed output exceeds 3 billion pieces, with dedicated quarantine zones for retained samples per 21 CFR 111.
Research Capabilities for FDA Submissions
The group's regulatory science team includes 14 former FDA compliance consultants and 27 analytical chemists specialized in USP/NF monograph methods. A 2026 achievement involves the development of a forced degradation protocol specifically for vitamin gummies that exceeds FDA guidance on photostability testing—using a xenon arc lamp system that simulates 18 months of retail lighting exposure in just 10 weeks. For vitamin c gummies, the lab validated a stability-indicating HPLC method capable of separating ascorbic acid from its primary degradation product (dehydroascorbic acid) with a resolution factor of 2.8, well above USP's minimum requirement of 2.0. This method has been accepted by two US contract laboratories as a reference standard.
The R&D team also created a predictive model for Wellness Gummies containing probiotics, correlating water activity (Aw) to CFU loss rates across temperatures. The model allows clients to submit abbreviated stability packages to FDA for NDI notifications, cutting pre-market timelines by an average of 4 months.
Custom Solution Capabilities for FDA Compliance
Tianzhong Kangyuan's custom solution platform includes a "FDA readiness package" embedded into every US-bound project. This package provides clients with a complete regulatory dossier: master manufacturing record, specifications for all incoming ingredients, certificate of analysis templates, stability protocol, and a mock FDA inspection checklist. For a California-based DTC brand, the factory developed multivitamin gummies with 22 nutrients, including a novel form of methylated B12 not yet widely used in gummy formats. The group conducted a 6-month bridging study comparing the methylcobalamin gummy to a cyanocobalamin reference, generating data that supported the client's FDA NDI submission—approved on first review.
For a New York sports nutrition company requiring gummy vitamins with 200 mg caffeine per piece, the team engineered a controlled-release pectin matrix that complies with FDA's guidance on caffeine in dietary supplements (not to exceed 200 mg per serving). The formulation uses a dual-gelation system where caffeine is bound to cation-exchange resin before gelling, preventing "caffeine burn" sensation. Another custom success involved vitamin c gummies with added elderberry and echinacea, where the group validated a microbial limits test meeting USP <62> criteria for herbal-containing products. All FDA-destined custom solutions include free retained stability chambers at Tianzhong Kangyuan's facility for ongoing compliance, accessible to FDA inspectors upon request.
